Skip to main content
NYRADA INC. logo

NYRADA INC. — Investor Relations & Filings

Ticker · NYR ISIN · AU0000070195 ASX Professional, scientific and technical activities
Open in API
Filings indexed 472 across all filing types
Latest filing 2024-09-29 AGM Information
Country AU Australia
Listing ASX NYR

About NYRADA INC.

https://www.nyrada.com

Nyrada Inc. specializes in the development of novel small molecule therapeutic agents designed to address unmet needs in cardiovascular health and neuroprotection. The company’s lead programs include a cholesterol-lowering treatment and a neuroprotective treatment for brain injury. The cardiovascular program focuses on an oral PCSK9 inhibitor aimed at managing low-density lipoprotein (LDL) cholesterol levels as an alternative to injectable biologics. The neuroprotection program involves the development of NYR-BI03, a first-in-class small molecule designed to mitigate secondary brain damage following a stroke or traumatic brain injury by targeting canonical transient receptor potential (TRPC) ion channels. These efforts aim to provide effective, accessible pharmacological interventions for both chronic metabolic conditions and acute neurological trauma.

Recent filings

Filing Released Lang Actions
2024 Annual General Meeting Access Letter, Notice and Proxy 42 pages 1.9MB
AGM Information Classification · 100% confidence The document is titled '2024 AGM Letter to Shareholders, Notice of Meeting and Proxy' and contains detailed information about the upcoming Annual General Meeting (AGM) of Nyrada Inc. It includes the Notice of Meeting, proxy forms, voting instructions, resolutions to be voted on, and logistical details about the physical meeting. The content is focused on informing shareholders about the AGM, how to vote, and the agenda items, rather than presenting financial results or management analysis. The document length is about 15,000 characters, which is consistent with a detailed AGM notice and related materials. There is no financial data, earnings information, or audit content. The document is not a report publication announcement but the actual AGM materials. Therefore, the document fits the category of AGM Information (AGM-R).
2024-09-29 English
Brain Injury Program GLP Studies Further Update 5 3 pages 283.0KB
Regulatory Filings Classification · 95% confidence The document is a corporate announcement from Nyrada Inc providing an update on the progress of their Brain Injury Program GLP (Good Laboratory Practice) studies, specifically the completion of a dog toxicology study. It discusses preclinical study results, safety and tolerability data, and plans for a Phase I clinical trial. The content is focused on research and development progress and does not contain financial statements, regulatory certifications, voting results, or management changes. It is not a full financial report, earnings release, or investor presentation. The document is an operational update on a specific program milestone, typical of a Capital/Financing Update or RNS. However, since it relates to a clinical trial progress update and drug development milestone rather than financing or capital structure changes, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2024-09-26 English
Investor Presentation 17 pages 1.3MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation September 2024' and contains detailed information about Nyrada Inc's drug development programs, market opportunities, clinical trial designs, safety studies, and near-term catalysts. It includes forward-looking statements, disclaimers, and strategic information aimed at investors. There are no financial statements or regulatory filings such as annual or quarterly reports, audit reports, or earnings releases. The content is consistent with a presentation designed to inform investors about the company's business, strategy, and upcoming milestones. Therefore, the document fits the category of an Investor Presentation (IP). The document length (over 14,000 characters) and detailed content confirm it is the presentation itself, not just an announcement of a report.
2024-09-16 English
Brain Injury Program GLP Studies Further Update 4 3 pages 301.5KB
Capital/Financing Update Classification · 95% confidence The document is a corporate announcement dated 09 September 2024 from Nyrada Inc providing an update on the progress of Good Laboratory Practice (GLP) studies related to their Brain Injury drug candidate NYR-BI03. It details the completion of a dog cardiovascular safety study and references previous GLP studies, indicating ongoing research and development activities. The document does not contain financial statements, earnings data, or detailed financial analysis. It is not a full annual or interim report, nor is it a regulatory filing or certification. The content is an update on clinical and preclinical study progress, which is typical of a Capital/Financing Update or a general corporate update related to drug development progress. Given the focus on study results and progress towards clinical trials, this fits best under Capital/Financing Update (CAP), as it relates to the company's development pipeline and progress that could impact financing or capital markets perception. The document length is about 4800 characters, which is consistent with a detailed announcement but not a full report. Therefore, the classification is CAP with high confidence.
2024-09-08 English
Preliminary final report 2 pages 160.9KB
Regulatory Filings Classification · 95% confidence The document is titled 'Nyrada Inc. Appendix 4E Preliminary final report' and covers the financial results for the year ended 30 June 2024. It includes detailed financial data such as revenues, losses, net tangible assets, and audit information. The document states that the Annual Report for the year ended 30 June 2024 is attached, indicating this document is a preliminary final report rather than the full Annual Report itself. Appendix 4E is a regulatory filing used in Australia to announce preliminary final results before the full Annual Report is released. The document length is 2665 characters, which is relatively short and consistent with a preliminary announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a preliminary announcement of financial results and not the full Annual Report (10-K) or Interim Report (IR).
2024-08-21 English
Appendix 4G and Corporate Governance Statement 25 pages 904.0KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G and Corporate Governance Statement' and references the ASX Listing Rules 4.7.3 and 4.10.3, which relate to corporate governance disclosures for Australian listed entities. It includes an Appendix 4G, which is a key to disclosures under the ASX Corporate Governance Council Principles and Recommendations, and a Corporate Governance Statement. The document explicitly states that the Corporate Governance Statement is available on the company's website and is approved by the board. The document is an announcement attaching these governance-related documents for the fiscal year ended 30 June 2024. It does not contain full financial statements or detailed annual report content but focuses on governance disclosures and compliance with listing rules. Given the nature of the content and the focus on governance disclosures rather than a full annual report, the document fits best under the category of Governance Information (CGR).
2024-08-21 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.